St. Jude Expands Cardio Facility

St. Jude Medical Inc. is expanding its facility in Plymouth, Minn. The construction project is designed to expand the company’s current facilities and consolidate operations for its cardiovascular division.

St. Jude’s board recently approved plans to add a three-story, 275,000-square-foot addition to its existing Plymouth building, consolidating the company’s current cardiovascular division leased locations in Minnetonka and Maple Grove with existing operations at the site. The company expects the construction to be completed in 2013.

“Because many of the future growth opportunities for St. Jude Medical are expected to arise from devices in the cardiovascular division, we’re excited to develop a Plymouth Campus that will not only help streamline operations and business activities, but also bring employees together under one roof,” said Frank J. Callaghan, president of the St. Jude Medical’s cardiovascular division. “This expansion is viewed as a consolidation and space solution for the company, but also acknowledges a need for adequate space to house our growing business in the years ahead.”

Designs for the Plymouth campus capture the look and feel of other St. Jude Medical buildings, including the company’s corporate headquarters in St. Paul as well as other new buildings in Brazil and Costa Rica, officials said. In line with those facilities, the expansion is expected to incorporate environmentally responsible and sustainable design. St. Jude Medical also planned for long-term growth at the Plymouth Campus with additional site upgrades that can be added at a later date. The company’s headquarters and atrial fibrillation division site in Little Canada are also planned for expansion.

The current building in Plymouth includes 205,000 square feet of space located on 26 acres of land. The site formerly served as the headquarters of AGA Medical, a company acquired by St. Jude Medical in 2010.

St. Jude Medical has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.